News | Heart Valve Technology | November 18, 2026

Capstan Medical Completes First U.S. TMVR Procedure with Investigational Robotic Mitral Valve Replacement System

Transcatheter procedure performed at The Christ Hospital using the Capstan Compass Robotic System.

Capstan Medical Completes First U.S. TMVR Procedure with Investigational Robotic Mitral Valve Replacement System

Capstan Medical’s investigational Capstan Compass Robotic System
in use during TMVR procedure, performed by The Christ Hospital Heart &
Vascular team under the leadership of Santiago Garcia, MD. 
(Photo: Capstan Medical)


Nov. 16, 2026 — Capstan Medical has announced the successful completion of its first U.S. robot-assisted transcatheter mitral valve replacement (TMVR) procedure. This marks an important advancement in developing its robotic-enabled, minimally invasive technology to treat heart valve disease.

The procedure was performed Nov. 9 at the Christ Hospital in Cincinnati, Ohio, by a team led by Santiago Garcia, MD, Director of the Structural Heart Program. The procedure was conducted as part of a U.S. Food and Drug Administration (FDA)-authorized early feasibility study.

“This first U.S. procedure represents another significant step forward in the treatment of structural heart disease. I am pleased to report that the procedure was successful, and the patient was discharged home in stable condition,” said Dr. Garcia. "The robotic platform is designed to provide catheter stability and control, enabling precise positioning of the mitral valve implant. This technology has the potential to fundamentally change what is possible for patients who cannot undergo conventional heart surgery, which remains an important unmet clinical need." 

Mitral regurgitation occurs when the mitral valve does not close properly, allowing blood to flow backward through the heart. Many patients are too high-risk for conventional surgery and the existing catheter-based treatments are not suitable for all patients.

TMVR Technology

Capstan's investigational TMVR technology combines a flexible, multi-axis catheter, robotic navigation and a novel valve implant. Designed to treat a greater number of mitral valve patients and overcome the challenges of navigating the heart's complex anatomy. The system gives physicians precise control over catheter movement, valve positioning and deployment during minimally invasive procedures. 

In lieu of managing multiple knobs on a traditional catheter systems, the Capstan System enables physicians to perform the TMVR procedure via inputs from a handheld controller with precise control over catheter movement, valve positioning and deployment. 

"This first U.S. case builds on our initial clinical experience and brings us another step closer to expanding treatment options to patients who need them most." said Maggie Nixon, Chief Executive Officer of Capstan Medical. "The Capstan technology lays the foundation for what heart valve intervention should be; simple, reproducible and low-stress. We couldn’t be more excited for this milestone that makes that future a reality." The milestone follows Capstan's pioneering first-in-human robotic-assisted mitral valve replacement procedures, completed in Chile and announced in March 2025. Dr. Garcia was also present in those procedures.

 

Capstan Medical TMVR

 


Additional Content

News | Robotic Systems

Nov. 2, 2026 — Canon Medical Systems USA has announced a technology compatibility and commercial collaboration to pair ...

Home November 06, 2026
Home
News | Robotic Systems

Nov. 2, 2026 — Stereotaxis announced the findings from the first-in-human clinical results for Robocath’s next ...

Home November 04, 2026
Home
News | Robotic Systems

Jan. 27, 2026 — Robocath has launched the world’s first FIH (First-In-Human) clinical study evaluating its new robotic ...

Home January 27, 2026
Home
News | Robotic Systems

Oct. 22, 2025 -- Medical robotics innovator Noah Medical presented two new data sets highlighting the clinical and ...

Home November 03, 2025
Home
News | Robotic Systems

June 11, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, today ...

Home June 11, 2024
Home
Subscribe Now